Dianthus Therapeutics (NASDAQ:DNTH) SVP Adam Veness Sells 30,000 Shares of Stock

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) SVP Adam Veness sold 30,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $80.80, for a total transaction of $2,424,000.00. Following the sale, the senior vice president directly owned 30,000 shares in the company, valued at approximately $2,424,000. This represents a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Dianthus Therapeutics Trading Up 0.7%

NASDAQ DNTH opened at $82.49 on Friday. The company has a fifty day simple moving average of $86.74 and a two-hundred day simple moving average of $66.27. The stock has a market cap of $4.51 billion, a P/E ratio of -19.97 and a beta of 1.18. Dianthus Therapeutics, Inc. has a 12-month low of $16.64 and a 12-month high of $96.50.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.85) EPS for the quarter, topping the consensus estimate of ($1.07) by $0.22. The business had revenue of $0.46 million during the quarter, compared to the consensus estimate of $0.40 million. Dianthus Therapeutics had a negative net margin of 12,998.50% and a negative return on equity of 27.30%. As a group, sell-side analysts forecast that Dianthus Therapeutics, Inc. will post -3.82 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have weighed in on DNTH shares. Raymond James Financial reiterated a “strong-buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Guggenheim restated a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Stifel Nicolaus set a $120.00 target price on Dianthus Therapeutics in a report on Monday, March 9th. TD Cowen reissued a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Finally, HC Wainwright lifted their price objective on shares of Dianthus Therapeutics from $47.00 to $130.00 and gave the company a “buy” rating in a research note on Monday, March 9th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Dianthus Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $117.82.

Hedge Funds Weigh In On Dianthus Therapeutics

Institutional investors have recently bought and sold shares of the company. PNC Financial Services Group Inc. boosted its holdings in Dianthus Therapeutics by 0.4% in the 1st quarter. PNC Financial Services Group Inc. now owns 37,360 shares of the company’s stock valued at $3,135,000 after purchasing an additional 139 shares during the last quarter. First Horizon Corp purchased a new stake in shares of Dianthus Therapeutics during the 1st quarter valued at approximately $32,000. Virtus Investment Advisers LLC raised its position in shares of Dianthus Therapeutics by 7.1% during the 4th quarter. Virtus Investment Advisers LLC now owns 6,315 shares of the company’s stock valued at $260,000 after buying an additional 416 shares during the period. Royal Bank of Canada lifted its holdings in Dianthus Therapeutics by 36.9% in the fourth quarter. Royal Bank of Canada now owns 2,012 shares of the company’s stock valued at $82,000 after acquiring an additional 542 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Dianthus Therapeutics by 4.2% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock valued at $280,000 after acquiring an additional 618 shares during the last quarter. 47.53% of the stock is owned by hedge funds and other institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.